Saturday, July 11, 2026

pharma · COPD

Kwong Wah Hospital

Kwong Wah Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include COPD. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from pub

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0
Clinical program

N-acetycysteine (600mg twice daily)

Approved · small molecule · COPD

N-acetycysteine (600mg twice daily) for COPD is a Approved program (small_molecule) at Kwong Wah Hospital with 1 ClinicalTrials.gov record(s).

← All Kwong Wah Hospital projects Approved small molecule completed

Internal code KW/EX/09-140

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Kwong Wah Hospital
Phase
Approved
Modality
small_molecule
Indication
COPD
Status
completed
Trials
1

Clinical trials